PMID- 21950735
OWN - NLM
STAT- MEDLINE
DCOM- 20120326
LR  - 20181201
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 11
IP  - 6
DP  - 2011 Dec 1
TI  - Pioglitazone is a valid alternative to rosiglitazone.
PG  - 357-62
LID - 10.2165/11595990-000000000-00000 [doi]
AB  - In 2000, two new thiazolidinediones, pioglitazone and rosiglitazone, were 
      approved for the treatment of type 2 diabetes mellitus (T2DM). Administered as 
      monotherapy or in combination with other antihyperglycemic agents, they 
      represented an effective option for achieving or maintaining good glycemic 
      control in patients with T2DM. Despite their efficacy, there was increasing 
      concern regarding the potential of an increased cardiovascular risk with 
      rosiglitazone. This resulted in the suspension of rosiglitazone from the European 
      market by the European Medicines Agency in September 2010. This article focuses 
      on the various steps that led to this important decision, and discusses a 
      possible alternative for the treatment of patients receiving rosiglitazone.
FAU - Derosa, Giuseppe
AU  - Derosa G
AD  - Department of Internal Medicine and Therapeutics, University of Pavia, Italy. 
      giuseppe.derosa@unipv.it
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Cardiovascular Diseases/chemically induced
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Europe
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Pioglitazone
MH  - Rosiglitazone
MH  - Safety-Based Drug Withdrawals
MH  - Thiazolidinediones/administration & dosage/adverse effects/*therapeutic use
EDAT- 2011/09/29 06:00
MHDA- 2012/03/27 06:00
CRDT- 2011/09/29 06:00
PHST- 2011/09/29 06:00 [entrez]
PHST- 2011/09/29 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
AID - 10.2165/11595990-000000000-00000 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2011 Dec 1;11(6):357-62. doi: 
      10.2165/11595990-000000000-00000.